Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to methods for detecting a genetic deletion at the SHOX locus of a horse, where the presence of such a genetic deletion indicates that the horse is a carrier of disease-causing mutation that can lead to skeletal atavism. The invention further provides nucleic acid primers and probes for use in methods for detecting the presence or absence of disease-causing genetic deletion at the SHOX locus of a horse.

Abstract: Provided herein are apparatus and methods relating to the development of instrumentation for high throughput network electrophysiology and cellular analysis. More specifically, provided herein are multiwell microelectrode arrays (MEAs) and methods for the development of such an apparatus in an inexpensive fashion with a flexible, ANSI/SBS-compliant (American National Standards Institute/Society for Biomolecular Screening) format. Microelectrode arrays are a grid of tightly spaced microelectrodes useful for stimulating and sensing electrically active cells, networks and tissue. The techniques described herein relate to the use of microfabrication in combination with certain large-area processes that have been employed to achieve multiwell MEAs in ANSI/SBS-compliant culture well formats, which are also transparent for inverted/backside microscopy compatibility.

Abstract: A lighting system includes circuitry to provide wireless LED driver or fluorescent ballast control without requiring changes to existing wiring setups. A power stage includes a power converter coupled across a first set of power terminals. The first power terminals are coupled to a second set of terminals via the wiring. A load stage is coupled to the second power terminals, wherein power provided across the first set of terminals is received by the load stage and deliverable to lighting devices. The load stage further includes a dimming control signal receiver coupled across the second set of power terminals and configured to receive an encoded dimming control signal. The encoded signal is transmitted across the wiring setup, wherein the power stage further includes a dimming control signal decoder coupled across the first set of power terminals and effective to deliver a decoded dimming control signal to the controller.

Abstract: The present invention provides compositions and methods for the delivery of nucleic acids to a cell. The present invention additionally provides compositions and methods for the treatment of a disease or disorder, particularly cancer. In a particular embodiment, the composition comprises at least one pharmaceutically acceptable carrier and at least one liposome or dendrimer comprising at least two chemotherapeutic agents with different mechanisms of action and at least two inhibitors of cellular drug resistance.

Abstract: The present invention relates to an expression vector containing the major envelope protein P9 of Cystovirus phi12 as a fusion partner, and a process for producing a membrane protein using the same. Particularly, the present invention is directed to an expression vector comprising a major envelope protein P9 gene of Cystovirus phi12, a multicloning site (MCS) for inserting a target membrane protein, and a protease recognition site located between a P9 gene and the MCS.

Abstract: An IR imaging system comprising microelectromechanical systems (MEMS) differential capacitive infrared sensors within a sensor array formed on a monolithic integrated circuit substrate, or flip chip bonded onto a signal processing chip fabricated separately, to include, a bimaterial deflectable element anchored to the substrate, a surface electrode fabricated on a top surface of the substrate and positioned below the deflectable element, the surface electrode and the deflectable element separated by a gap to form a first variable capacitor, a sealing ring surrounding the deflectable element and the surface electrode, an infrared transparent sealing cap electrode coupled to the sealing ring to form a vacuum cavity around the deflectable element and the surface electrode, the deflectable element and the sealing cap electrode separated by a gap to form a second variable capacitor and a micro-lens fabricated on the sealing cap electrode to focus the infrared radiation onto the bimaterial deflectable element.

Abstract: Provided are TRPV4 inhibitor compounds. Further provided are compositions including a TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application. The TRPV4 inhibitor compounds and compositions may be used in methods of treating and/or preventing dermatological disorders, reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof.

Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

Abstract: The present invention is directed to the detection of problematic foaming and bulking bacterial species in the biological wastewater treatment process. The invention provides various compositions of matter and methods for the detection of foaming and bulking bacterial species and genera in wastewater and other samples. PCR primers capable of amplifying 16s rRNA gene sequences from various foaming and bulking bacterial species are provided, as are probes that will specifically hybridize with PCR amplification products produced by the disclosed primers. In certain embodiments, the use of the disclosed PCR primers and probes in detection assays is disclosed.

Abstract: A modular IOL system including intraocular primary and secondary components, which, when combined, form an intraocular optical correction device, wherein the secondary component is placed on the primary component within the perimeter of the capsulorhexis, thus avoiding the need to touch or otherwise manipulate the capsular bag. The secondary component may be manipulated, removed, and/or exchanged for a different secondary component for correction or modification of the optical result, on an intra-operative or post-operative basis, without the need to remove the primary component and without the need to manipulate the capsular bag. The primary component may have haptics extending therefrom for centration in the capsular bag, and the secondary component may exclude haptics, relying instead on attachment to the primary component for stability. Such attachment may include actuatable interlocking members.

Abstract: A power control device includes a first terminal, a second terminal connected to a transmission line, a first cascade multilevel inverter (CMI) and a second CMI. The first CMI is connected to the second terminal. The second CMI connected in series between the first terminal and the second terminal.

Abstract: A process for synthesizing 4-amino-2,4-dioxobutanoate involves reacting a dialkyl oxalate with an alkoxide in ethanol to form a reaction mixture, and afterward adding an alkyl cyano acetate to the reaction mixture and allowing a reaction to proceed under conditions suitable to form a first reaction product of the formula diethyl 2-cyano-3-hydroxy-butenedioate, and then isolating the diethyl 2-cyano-3-hydroxy-butenedioate, and afterward reacting the diethyl-2-cyano-3-hydroxy-butenedioate with an aqueous hydroxide under conditions suitable to form 4-amino-2,4-dioxobutanoate. The 4-amino-2,4-dioxobutanoate may be acidified into 4-amino-2,4-dioxobutanoic acid.

Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

Abstract: The present invention relates to compositions and methods for the preparation, stabilization, and/or storage of active agents, particularly therapeutic proteins and polypeptides such as Interleukin-2.

Abstract: Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound.

Abstract: Reagents and methods for treating dental disease are provided.

Abstract: The present invention relates to a method for making high surface area and large pore volume thermally stable silica-doped alumina (aluminum oxide) catalyst support and ceramic materials. The ability of the silica-alumina to withstand high temperatures in presence or absence of water and prevent sintering allows it to maintain good activity over a long period of time in catalytic reactions. The method of preparing such materials includes adding organic silicon reagents to an organic aluminum salt such as an alkoxide in a controlled quantity as a doping agent in a solid state, solvent deficient reaction followed by calcination. Alternatively, the organic silicon compound may be added after calcination of the alumina, followed by another calcination step. This method is inexpensive and simple. The alumina catalyst support material prepared by the subject method maintains high pore volumes, pore diameters and surface areas at very high temperatures and in the presence of steam.

Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

Abstract: A simulated weapon or firearm is provided that is formed with a mechanical operating or firing mechanism similar to that of an actual firearm. The firing mechanism is formed with components found in an actual firearm that are interconnected with components of an electronic mechanism that can monitor and control the mechanical operation of the simulated firearm. This allows for the mechanical operating mechanism to function in a manner similar to that of an actual firearm, while the electronic mechanism can introduce various mechanical failures that do not otherwise occur in the electronics-only operating mechanisms of prior simulated firearms. In addition, the operational cycles of the mechanical and electronic mechanisms are synchronized to provide a highly realistic feel to the simulated weapon.